Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2008 Financial Results

Keryx to Host Investor Conference Call on Tuesday, November 11, 2008 at

8:30am EST

NEW YORK, Nov. 10 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer, today announced its results for the third quarter ended September 30, 2008.

At September 30, 2008, the Company had cash, cash equivalents, investment securities and interest receivable of $26.5 million, as compared to $64.7 million at December 31, 2007. Approximately $9.2 million of the Company's investments, at September 30, 2008, represent auction rate securities, which are classified as long-term investments.

The net loss for the third quarter ended September 30, 2008 was $6,841,000, or $0.15 per share, compared to a net loss of $19,528,000, or $0.45 per share, for the comparable quarter in 2007, representing a decrease in net loss of $12,687,000. The decrease in net loss was primarily attributable to a $11,699,000 decrease in research and development expenses related to the cessation of the development of Sulonex in March 2008, a $1,860,000 decrease in expenses related to our other clinical compounds, and a $519,000 decrease in non-cash compensation expense related to equity incentive grants, partially offset by a $1,639,000 decrease in interest and other income (expense), net.

Commenting on the quarter, Michael S. Weiss, Keryx's Chairman and Chief Executive Officer, said, "During the third quarter, we continued to make progress in our Zerenex and Perifosine clinical programs, while operating with a lean overhead structure." Weiss continued, "We expect our cash burn to be approximately $3 million for the remaining three months of 2008, and intend to continue to focus our resources on creating value in our product portfolio."

On Tuesday, November 11, 2008, at 8:30am EST, the Company will host an investor conference call during which they will provide a brief financial overview of the Company's third quarter financial results.

In order to participate in the conference call, please call 1-877-407-8289 (U.S.), 1-201-689-8341 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at, for a period of 15 days after the call.


Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. The Company also has an in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release may be forward- looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to complete cost-effective clinical trials or meet, as anticipated, the development timelines for the drug candidates in our pipeline, including Zerenex and KRX-0401; our ability to maintain the projected cash burn rate while successfully completing our clinical trials; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.

KERYX CONTACT: Lauren Fischer

Director - Investor Relations

Keryx Biopharmaceuticals, Inc.

Tel: 212.531.5965


Keryx Biopharmaceuticals, Inc.

Selected Consolidated Financial Data

(Thousands of Dollars, Except Share and Per Share Data)

Statements of Operations Information:

Three Months Ended Nine Months Ended

September 30, September 30,

(unaudited) (unaudited)

2008 2007 2008 2007


License revenue $327 $41 $853 $41

Service revenue 41 11 103 37

TOTAL REVENUE 368 52 956 78


Cost of services 13 28 27 90

Research and development:

Non-cash compensation 334 735 (395) 2,908

Other research and

development 2,208 15,965 37,277 49,093

Total research and

development 2,542 16,700 36,882 52,001

Selling, general and administrative:

Non-cash compensation 1,662 1,780 5,146 5,193

Other selling, general

and administrative 2,284 2,062 6,249 6,531

Total selling,

general and

administrative 3,946 3,842 11,395 11,724

TOTAL OPERATING EXPENSES 6,501 20,570 48,304 63,815

OPERATING LOSS (6,133) (20,518) (47,348) (63,737)


Interest and other

(expense) income, net (622) 1,017 (1,551) 3,658


OPERATIONS (6,755) (19,501) (48,899) (60,079)

Loss from discontinued

operations (86) (27) (175) (722)

NET LOSS $(6,841) $(19,528) $(49,074) $(60,801)




operations $(0.15) $(0.45) $(1.11) $(1.38)


operations $(--) * $(--) * $(--) * $(0.02)

Basic and diluted net

loss per common share $(0.15) $(0.45) $(1.11) $(1.40)



Basic and

diluted 45,222,053 43,619,523 44,348,537 43,561,160

Balance Sheet Information (unaudited):

September 30, December 31,

2008 2007

Cash, cash equivalents, interest receivable

and short-term investment securities $17,306 $62,386

Long-term investment securities 9,213 2,296

Total assets 30,702 81,061

Accumulated deficit (327,348) (278,274)

Stockholders' equity 321 44,422

* Amount less than one cent.

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Keryx Biopharmaceuticals KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2008 Financial Results on Tuesday, November 11, at 8:30 A.M. EST
3. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
5. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
6. Transition Therapeutics Announces First Quarter Fiscal 2009 Financial Results
7. Bradmer announces 2008 third quarter operational and financial results
8. Hillenbrand, Inc. Announces Fourth-Quarter Earnings Release Date and Conference Call
9. TransTech Services Partners Inc. Announces Election of Dr. Ranga C. Krishna as a Director
10. URAC Announces Finalists for Best Practices in Health Care Consumer Empowerment and Protection Awards
11. Heska Announces Q3 2008 Results
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... Volpara ... breast density assessment and enterprise analytics solutions, here at the 101st Annual ... Hall booth #2377). Volpara’s quantitative breast imaging tools enable personalized measurements of ...
(Date:11/30/2015)... York (PRWEB) , ... November 30, 2015 , ... Sikka ... New York Dental Meeting. Their Ecosystem empowers dentists to make complex business decisions by ... the booth will receive a free fee survey with 10 procedures customized by zip ...
(Date:11/30/2015)... ... , ... Scott Newman MD, FACS of New York’s Advanced ... in the New York City area to utilize the new, non-invasive SculpSure™ Laser ... treatment for fat loss in the abdomen, flanks, and other areas that is ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... today released the results of a survey of educational needs for pharmacists worldwide. ... a growing global demand for high quality online and face-to-face education for pharmacists ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... announces the Unstoppable Swappables, a household invention that provides an economical and easy ... a year and is growing at 2.6%," says Scott Cooper, CEO and Creative ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... -- Booth #4303 – The Imaging Components business of Varian ... array of products in a new booth (#4303) at the ... America in Chicago this ... components "At the Heart of Imaging." Products will include a ... Claymount brand, and computer-aided diagnostic software from MeVis as well ...
(Date:11/30/2015)... -- Hanger, Inc. (NYSE: HGR ) (the "Company") today ... its previously announced consent solicitation (as amended and restated, ... amount 7⅛% Senior Notes due 2018 (the "Notes") to ... pursuant to the Consent Solicitation, (ii) the proposed increased ... date of the Consent Solicitation.    ...
(Date:11/30/2015)... , Nov. 30, 2015   VolitionRx Limited (NYSE ... diagnostic tests for a broad range of cancer types and ... LD Micro Conference, which will be held December 1 - 3 ... from VolitionRx will be David Kratochvil , Chief Financial ... of Investor Relations. ® blood-based tests for ...
Breaking Medicine Technology: